Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Bloodstream Infections: Study of a 2-State Monoclonal Outbreak

Objective. To characterize the clinical outcomes of patients with bloodstream infection caused by carbapenem-resistant Acinetobacter baumannii during a 2-state monoclonal outbreak. Design. Multicenter observational study. Setting. Four tertiary care hospitals and 1 long-term acute care hospital. Methods. A retrospective medical chart review was conducted for all consecutive patients during the period January 1, 2005, through April 30, 2006, for whom 1 or more blood cultures yielded carbapenem-resistant A. baumannii. Results. We identified 86 patients from the 16-month study period. Their mortality rate was 41%; of the 35 patients who died, one-third (13) had positive blood culture results for carbapenem-resistant A. baumannii at the time of death. Risk factors associated with mortality were intensive care unit stay, malignancy, and presence of fever and/or hypotension at the time blood sample for culture was obtained. Only 5 patients received adequate empirical antibiotic treatment, but the choice of treatment did not affect mortality. Fifty-seven patients (66.2%) had a single positive blood culture result for carbapenem-resistant A. baumannii; the only factor associated with a single positive blood culture result was the presence of decubitus ulcers. Interestingly, during the study period, a transition from single to multiple positive blood culture results was observed. Four patients, 3 of whom were in a burn intensive care unit, were bacteremic for more than 30 days (range, 36–86 days). Conclusions. To our knowledge, this is the first time a study has described 2 patterns of bloodstream infection with A. baumannii: single versus multiple positive blood culture results, as well as a subset of patients with prolonged bacteremia.

[1]  K. Ko,et al.  Extreme Drug Resistance in Acinetobacter baumannii Infections in Intensive Care Units, South Korea , 2009, Emerging infectious diseases.

[2]  S. Jamulitrat,et al.  Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection. , 2009, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[3]  K. Sepkowitz,et al.  Multidrug-Resistant Acinetobacter baumannii in New York City—10 Years Into the Epidemic , 2009, Infection Control & Hospital Epidemiology.

[4]  Harald Seifert,et al.  Acinetobacter baumannii: Emergence of a Successful Pathogen , 2008, Clinical Microbiology Reviews.

[5]  M. Millar,et al.  Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance , 2008, European Journal of Clinical Microbiology & Infectious Diseases.

[6]  R. Weinstein,et al.  Acinetobacter infection. , 2008, The New England journal of medicine.

[7]  W. Chie,et al.  Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. , 2007, Diagnostic microbiology and infectious disease.

[8]  J. Quinn,et al.  Dissemination of Acinetobacter baumannii Clones with OXA-23 Carbapenemase in Colombian Hospitals , 2007, Antimicrobial Agents and Chemotherapy.

[9]  K. Ko,et al.  Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. , 2007, The Journal of antimicrobial chemotherapy.

[10]  M. Kaufmann,et al.  Occurrence of Carbapenem-Resistant Acinetobacter baumannii Clones at Multiple Hospitals in London and Southeast England , 2006, Journal of Clinical Microbiology.

[11]  P. Nordmann,et al.  Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  J. Quinn,et al.  Multicity Outbreak of Carbapenem-Resistant Acinetobacter baumannii Isolates Producing the Carbapenemase OXA-40 , 2006, Antimicrobial Agents and Chemotherapy.

[13]  J. Desenclos,et al.  VEB-1 Extended-Spectrum β-lactamase–producing Acinetobacter baumannii, France , 2006, Emerging Infectious Diseases.

[14]  J. Desenclos,et al.  VEB-1 Extended-spectrum beta-lactamase-producing Acinetobacter baumannii, France. , 2006, Emerging infectious diseases.

[15]  D. Landman,et al.  Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Weinstein,et al.  Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.